Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
Latest Information Update: 10 Mar 2022
At a glance
- Drugs Cobimetinib (Primary) ; Peginterferon (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms VEMUPLINT
- 10 Mar 2022 This trial has been discontinued, according to European Clinical Trials Database record.
- 07 Jun 2019 Status changed from recruiting to completed.
- 18 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.